share_log

Arcutis Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Watanabe Todd Franklin

Arcutis Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Watanabe Todd Franklin

Arcutis Biotherapeutics | 4：持股變動聲明-高管 Watanabe Todd Franklin
美股sec公告 ·  05/04 04:29
牛牛AI助理已提取核心訊息
Todd Franklin Watanabe, associated with Arcutis Biotherapeutics, completed a sale of 13,783 shares of common stock on May 2, 2024. The transaction was executed at a price of $8.7378 per share, resulting in a total sale value of approximately $120,433. Following the sale, Watanabe directly holds 860,750 shares of the company. The sale took place in the open market and was part of a planned disposition of shares. Additionally, Watanabe has indirect beneficial ownership of 231,140 shares through trusts and an LLC.
Todd Franklin Watanabe, associated with Arcutis Biotherapeutics, completed a sale of 13,783 shares of common stock on May 2, 2024. The transaction was executed at a price of $8.7378 per share, resulting in a total sale value of approximately $120,433. Following the sale, Watanabe directly holds 860,750 shares of the company. The sale took place in the open market and was part of a planned disposition of shares. Additionally, Watanabe has indirect beneficial ownership of 231,140 shares through trusts and an LLC.
與Arcutis Biotherapeutics相關的渡邊託德·富蘭克林於2024年5月2日完成了13,783股普通股的出售。該交易以每股8.7378美元的價格執行，總銷售價值約爲120,433美元。出售後，渡邊直接持有該公司860,750股股份。此次出售是在公開市場上進行的，是計劃處置股票的一部分。此外，渡邊通過信託和有限責任公司間接擁有231,140股股票的受益所有權。
與Arcutis Biotherapeutics相關的渡邊託德·富蘭克林於2024年5月2日完成了13,783股普通股的出售。該交易以每股8.7378美元的價格執行，總銷售價值約爲120,433美元。出售後，渡邊直接持有該公司860,750股股份。此次出售是在公開市場上進行的，是計劃處置股票的一部分。此外，渡邊通過信託和有限責任公司間接擁有231,140股股票的受益所有權。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。